Aminosalicylates and Other Anti-Inflammatory Compounds for Irritable Bowel Syndrome

  title={Aminosalicylates and Other Anti-Inflammatory Compounds for Irritable Bowel Syndrome},
  author={Giovanni Barbara and Vincenzo Stanghellini and Cesare Cremon and Roberto De Giorgio and Lucia Fronzoni and Mauro Serra and Roberto Corinaldesi},
  journal={Digestive Diseases},
  pages={115 - 121}
Growing evidence suggests that gastrointestinal immune activation may affect intestinal function and sensory perception, which contribute to symptom generation in patients with irritable bowel syndrome (IBS). The identification of higher counts of immunocytes (e.g. T cells and mast cells), mucosal and systemic immune activation, and increased mucosal permeability in patients with IBS has stimulated interest in the potential development of therapeutic approaches aimed at targeting the immune… 

The Immune System in Irritable Bowel Syndrome

Gender, age, geographic differences, genetic predisposition, diet and differences in the intestinal microbiota likely play a role and further research has to be done to clarify their relevance as potential mechanisms in the described immune system dysregulation.

Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside

This review focuses on recent advances in the role of mast cells in IBS, with particular emphasis on bridging experimental data with clinical therapeutics for IBS patients.

New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond

This literature review aims to summarize the findings related to new and investigational therapeutic agents for IBS, most recently developed in preclinical as well as Phase 1 and Phase 2 clinical studies.

Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome

Eluxadoline showed a low rate of constipation development in IBS patients in comparison with known effects of other opioid receptor modulators, and its efficacy over placebo has been demonstrated in short- and long-term clinical studies in humans.

The Role of Pathogenic Microbes and Commensal Bacteria in Irritable Bowel Syndrome

Proof of concept that pathogenic microbes can induce persistent gut dysfunction and that changes in microbial composition of the gut can maintain gut dysfunction as well as induce behavioral changes reminiscent of the psychiatric comorbidity that occurs in up to 60% of irritable bowel syndrome patients is provided.

Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome

Mesalazine significantly reduced pain intensity and duration and improved cytohistologic parameters of the bowel mucosa following the treatment of patients suffering from irritable bowel syndrome with mesalazine.

Inflammation in irritable bowel syndrome: Myth or new treatment target?

The aim of this review was to summarize the evidence on the spectrum of mucosal inflammation in IBS, highlighting the relationship of this inflammation to the pathophysiology of IBS and its connection to clinical practice.

Interferon-γ is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism.

It is suggested that IFN-γ downregulates SERT expression, hence likely playing a role in altered serotonin metabolism of patients with IBS.

Irritable bowel syndrome

The past decade has seen remarkable progress in the understanding of functional bowel disorders such as IBS that will be summarized in this Primer.

Effect of Red Pepper on Symptoms of Irritable Bowel Syndrome: Preliminary Study

The results of this preliminary study indicate that the chronic administration of red pepper powder in IBS patients with enteric-coated pills was significantly more effective in decreasing the intensity of abdominal pain and bloating and was considered by the patients more effective than placebo.



Mucosal Immune Activation in Irritable Bowel Syndrome: Gender-Dependence and Association With Digestive Symptoms

A large subset of IBS patients shows gender-dependent mucosal infiltration of immunocytes that correlates with abdominal bloating and dysmotility-like dyspepsia, and provides the rationale for considering immune mechanisms as a pathophysiological component in a subset ofIBS patients.

New pathophysiological mechanisms in irritable bowel syndrome

Initial evidence suggests the existence of changes in gut microflora, serotonin metabolism and a genetic contribution in IBS pathophysiology, which may aid a better understanding of the complex pathophys physiology of IBS and to develop new therapies.

Role for protease activity in visceral pain in irritable bowel syndrome.

It is established that proteases are released in IBS and that they can directly stimulate sensory neurons and generate hypersensitivity symptoms through the activation of PAR2.

Postinfectious irritable bowel syndrome.

A small but significant subgroup of patients with irritable bowel syndrome (IBS) report a sudden onset of their IBS symptoms after a bout of gastroenteritis, and some preliminary human data suggest this leads to excessive serotonin release from the mucosa.

Activation of the mucosal immune system in irritable bowel syndrome.

Examination of colonoscopic biopsy specimens from patients meeting the Rome criteria for a clinical diagnosis of irritable bowel syndrome showed subgroups with normal and abnormal conventional histology, implicating the mucosal immune system in pathogenesis.

Increased mast cells in the irritable bowel syndrome

  • O’SullivanClayton O’morain
  • Medicine, Biology
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2000
MC were significantly increased in the caecum of IBS patients compared to controls, suggesting that the multiple effects of the intestinal mast cell alone, or as a participant of a persistent inflammatory response, may be fundamental to the pathogenesis of Ibs.

The mode of action of the aminosalicylates in inflammatory bowel disease

It seems likely that the aminosalicylates are important free radical scavengers, can reduce leukotriene production and can inhibit the cellular release of interleukin‐1, all of which are likely to be important in reducing the acute inflammatory response in inflammatory bowel disease.

Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.

B infantis 35624 alleviates symptoms in IBS; this symptomatic response was associated with normalization of the ratio of an anti-inflammatory to a proinflammatory cytokine, suggesting an immune-modulating role for this organism, in this disorder.

Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome.

Mucosal mast cell mediators from IBS patients excite rat nociceptive visceral sensory nerves in vitro, providing new insights into the mechanism underlying visceral hypersensitivity in IBS.